What’s Behind Codan (ASX:CDA) Shares Moving Today?
Codan (ASX:CDA) has moved back into focus after its full year 2026 results showed sales of A$874.97m and net income of A$175.18m, alongside management’s renewed emphasis on acquisitions.
See our latest analysis for Codan.
The strong full year 2026 result and renewed acquisition focus come alongside powerful momentum in Codan’s stock, with a 30 day share price return of 16.77% and a year to date share price return of 68.44%. Over longer horizons, total shareholder returns have been very large, including an 88.64% 1 year total shareholder return and a 3 year total shareholder return of more than 7x, which points to investors steadily reassessing Codan’s growth prospects and risk profile.
If Codan’s run has you thinking about where growth and capital allocation could go next, it may be worth scanning other companies through the 4 top founder-led companies
Bulls point to Codan’s earnings jump and acquisition firepower. Bears focus on how much optimism is already in a stock that has risen sharply. The valuation numbers now give you evidence to weigh which side holds more ground.
Most Popular Narrative: 15% Overvalued
Coding the numbers in, the most followed narrative sees Codan’s fair value at A$42.61, which sits below the latest close of A$48.88.
Codan's disciplined M&A strategy, strong balance sheet, and expanded credit facility provide financial flexibility to pursue acquisitions that add complementary technologies, broaden end markets, and drive both revenue synergies and cost efficiencies, supporting sustained earnings growth and higher long-term returns.
Curious how that acquisition story translates into the A$42.61 fair value? The narrative leans heavily on compounded revenue growth, rising margins, and a richer earnings multiple. The key is how those three ingredients are expected to work together over several years.
Result: Fair Value of A$42.61 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there is still meaningful risk to this Codan narrative if gold detection demand weakens or if defence and public safety contracts prove lumpier than expected.
Find out about the key risks to this Codan narrative.
Next Steps
With sentiment this strong around Codan, it makes sense to move quickly and test the story against the underlying numbers yourself. To see what investors are optimistic about, review the 2 key rewards.
Looking for more investment ideas beyond Codan?
If Codan has sharpened your interest, do not stop here. Use the screener to uncover fresh opportunities that fit your style before the crowd catches on.
- Spot potential value opportunities early by scanning 14 high quality undervalued stocks that combine quality fundamentals with pricing that may not fully reflect their underlying strength.
- Strengthen your focus on resilience by checking 10 resilient stocks with low risk scores that score well on financial stability and lower business risk.
- Hunt for lesser-known opportunities by reviewing the screener containing 11 high quality undiscovered gems before they attract wider attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Moderna nearly tripled overnight, and every other mRNA stock jumped with it. I think that could be a trap.

Happy for the melanoma patients. It is no surprise that other companies moved up too. It's the optionality getting priced in.
There’s a 60% to 85% probability of the vaccine being approved based on historical drug development data. Could be a lot of scrutiny by the FDA due to the novel platform used.
Market might be getting a little ahead of itself here.
About ASX:CDA
Codan
Develops technology solutions for United Nations organizations, security and military agencies, government departments, corporates, individuals consumers, and small-scale miners.
Outstanding track record with excellent balance sheet.